Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia

Victor H. Jimenez-ZepedaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada

Donna E. ReeceDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada

Suzanne TrudelDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada

Christine ChenDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada

Rodger TiedemannDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada

Vishal KukretiDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, CanadaCorrespondence[email protected]

Click to increase image sizeClick to decrease image size

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia

Potential conflict of interest

Information for

Open access

Opportunities

Help and information

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature